Literature DB >> 16210916

Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel.

Nicola F Smith1, Milin R Acharya, Neil Desai, William D Figg, Alex Sparreboom.   

Abstract

Interindividual variability in paclitaxel and docetaxel pharmacokinetics, toxicity and response is extensive, and largely unexplained. We hypothesized that this is due to affinity of taxanes for an uptake transporter that indirectly regulates elimination pathways. Here, we studied accumulation of [3H]docetaxel and [3H]paclitaxel in Xenopus laevis oocytes injected with cRNA of the liver-specific organic anion transporting polypeptide (OATP) family members OATP1B1 (OATP2) or OATP1B3 (OATP8). Taxane transport by OATP1B1 expressing oocytes was not significantly different from that by water-injected controls, whereas uptake by OATP1B3 was 2.2-fold higher for docetaxel (p = 0.0007) and 3.3-fold higher for paclitaxel (p < 0.0001). OATP1B3-mediated paclitaxel transport was saturable (Michaelis-Menten constant, 6.79 microM), time-dependent, and highly sensitive to chemical inhibition. Paclitaxel uptake was not inhibited by ketoconazole or tariquidar. However, uptake was inhibited by the formulation excipient Cremophor (74.4% inhibition, p < 0.0001), cyclosporin A (25.2%, p = 0.005), glycyrrhizic acid (24.6%, p = 0.012), and hyperforin (28.4%, p = 0.003). Consistent with this finding, Cremophor was found to significantly affect the hepatic uptake of paclitaxel in mice. These data suggest that OATP1B3 is a key regulator of hepatic uptake, and may therefore play a role in the variable response to treatment with taxanes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16210916     DOI: 10.4161/cbt.4.8.1867

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  69 in total

1.  Identification of novel functional organic anion-transporting polypeptide 1B3 polymorphisms and assessment of substrate specificity.

Authors:  Ute I Schwarz; Henriette E Meyer zu Schwabedissen; Rommel G Tirona; Atsuko Suzuki; Brenda F Leake; Younes Mokrab; Kenji Mizuguchi; Richard H Ho; Richard B Kim
Journal:  Pharmacogenet Genomics       Date:  2011-03       Impact factor: 2.089

Review 2.  OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies.

Authors:  Megan Roth; Amanda Obaidat; Bruno Hagenbuch
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

3.  Physiological modeling to understand the impact of enzymes and transporters on drug and metabolite data and bioavailability estimates.

Authors:  Huadong Sun; K Sandy Pang
Journal:  Pharm Res       Date:  2010-04-06       Impact factor: 4.200

4.  Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3.

Authors:  Chunshan Gui; Yi Miao; Lucas Thompson; Bret Wahlgren; Melissa Mock; Bruno Stieger; Bruno Hagenbuch
Journal:  Eur J Pharmacol       Date:  2008-02-08       Impact factor: 4.432

5.  Amino acid residues in transmembrane domain 10 of organic anion transporting polypeptide 1B3 are critical for cholecystokinin octapeptide transport.

Authors:  Chunshan Gui; Bruno Hagenbuch
Journal:  Biochemistry       Date:  2008-08-09       Impact factor: 3.162

Review 6.  Uptake carriers and oncology drug safety.

Authors:  Jason A Sprowl; Alex Sparreboom
Journal:  Drug Metab Dispos       Date:  2013-12-30       Impact factor: 3.922

Review 7.  Clinical Pharmacokinetics of Paclitaxel Monotherapy: An Updated Literature Review.

Authors:  Tore B Stage; Troels K Bergmann; Deanna L Kroetz
Journal:  Clin Pharmacokinet       Date:  2018-01       Impact factor: 6.447

8.  Role of transmembrane domain 10 for the function of organic anion transporting polypeptide 1B1.

Authors:  Chunshan Gui; Bruno Hagenbuch
Journal:  Protein Sci       Date:  2009-11       Impact factor: 6.725

Review 9.  Pharmacogenetics of membrane transporters: an update on current approaches.

Authors:  Tristan M Sissung; Caitlin E Baum; C Tyler Kirkland; Rui Gao; Erin R Gardner; William D Figg
Journal:  Mol Biotechnol       Date:  2010-02       Impact factor: 2.695

10.  Inhibition of OATP-1B1 and OATP-1B3 by tyrosine kinase inhibitors.

Authors:  Varun Khurana; Mukul Minocha; Dhananjay Pal; Ashim K Mitra
Journal:  Drug Metabol Drug Interact       Date:  2014
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.